Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial

被引：1
|
作者：
Kolkailah, Ahmed A. [1 ,2 ,6 ]
Lingvay, Ildiko [3 ]
Dobrecky-Mery, Idit [4 ]
Aharonovich, Alona [5 ]
David, Jens-Peter [5 ]
Holse, Cecilie [5 ]
Rasmussen, Soren [5 ]
McGuire, Darren K. [1 ,2 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX USA
[2] Parkland Hlth & Hosp Syst, Dallas, TX USA
[3] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Endocrinol, Dallas, TX USA
[4] Bnai Zion Med Ctr, Dept Cardiol, Haifa, Israel
[5] Novo Nordisk A S, Soborg, Denmark
[6] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Cardiol, 5323 Harry Hines Blvd,Suite E5-700, Dallas, TX 75235 USA
来源：
DIABETES OBESITY & METABOLISM | 2023年 / 25卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1111/dom.14941
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1117 / 1120
页数：4
相关论文
共 50 条
  • [1] Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
    Tuttle, Katherine R.
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Khunti, Kamlesh
    Rasmussen, Soren
    Sokareva, Ekaterina
    Cherney, David Z.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2006 - 2015
  • [2] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [3] Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide
    Berry, Sasha
    Chubb, Barrie
    Acs, Annabel
    Falla, Edel
    Verma, Akanksha
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Palmer, Andrew J.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1019 - 1031
  • [4] Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
    Aroda, V. R.
    Ahmann, A.
    Cariou, B.
    Chow, F.
    Davies, M. J.
    Jodar, E.
    Mehta, R.
    Woo, V
    Lingvay, I
    DIABETES & METABOLISM, 2019, 45 (05) : 409 - 418
  • [5] Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial
    Mentz, Robert J.
    Bethel, M. Angelyn
    Thompson, Vivian P.
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Julian C.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Holman, Rury R.
    Hernandez, Adrian F.
    CIRCULATION, 2017, 136 (24) : E455 - E455
  • [6] Once-weekly semaglutide vs canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
    Lingvay, I.
    Catarig, A.
    Frias, J. P.
    Kumar, H.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Viljoen, A.
    McCrimmon, R. J.
    DIABETOLOGIA, 2019, 62 : S27 - S28
  • [7] ECONOMIC IMPACT OF CARDIOVASCULAR BENEFIT OF ONCE-WEEKLY SEMAGLUTIDE IN TYPE 2 DIABETES PATIENTS WITH HIGH CARDIOVASCULAR RISK IN CHINA
    Zhen, R.
    Ung, C. O. L.
    Hu, H.
    VALUE IN HEALTH, 2021, 24 : S88 - S88
  • [8] Effects of once-weekly semaglutide vs canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial
    McCrimmon, R. J.
    Catarig, A.
    Frias, J. P.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Lingvay, I.
    DIABETOLOGIA, 2019, 62 : S29 - S29
  • [9] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    Holman, Rury R.
    Bethel, M. Angelyn
    Mentz, Robert J.
    Thompson, Vivian P.
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Juliana C.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13): : 1228 - 1239
  • [10] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
    Leiter, Lawrence A.
    Bain, Stephen C.
    Hramiak, Irene
    Jodar, Esteban
    Madsbad, Sten
    Gondolf, Theis
    Hansen, Thomas
    Holst, Ingrid
    Lingvay, Ildiko
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
12345